Summary: Axsome Therapeutics’ AXS-12 (reboxetine) achieved significant results in the ENCORE phase 3 trial for narcolepsy with cataplexy, reducing cataplexy attacks by 77% over six months and improving excessive daytime sleepiness, cognition, and overall narcolepsy symptoms. The … [Read more...]